WO2000052163A1 - Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer - Google Patents
Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer Download PDFInfo
- Publication number
- WO2000052163A1 WO2000052163A1 PCT/US2000/005346 US0005346W WO0052163A1 WO 2000052163 A1 WO2000052163 A1 WO 2000052163A1 US 0005346 W US0005346 W US 0005346W WO 0052163 A1 WO0052163 A1 WO 0052163A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mage
- seq
- nucleic acid
- acid molecule
- isolated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Definitions
- This invention relates to nucleic acid molecules which are members of the MAGE
- MHC or HLA molecules form complexes with MHC or HLA molecules, fusion proteins, polytopes, and so forth.
- HLAs human immunoglobulins
- MAGE-B cluster of genes are referred to as the MAGE-B cluster of genes. Additional MAGE family members have been located at region q26, and have been named
- RT-PCR reverse transcription-polymerase chain reaction
- Testis expresses all MAGE-A
- lymphocyte-tumor cell culture The lymphocyte-tumor cell culture.
- Figure 1 presents exon/intron structures of MAGE genes, including for MAGE-
- the first pair is described by De Plaen, et al.,
- CTGGGTAAAG ACTCACTGTC TGG (SEQ ID NO: 2)
- SEQ ID NOS: 3&4 correspond to sequences complementary to the last exon of
- the frequency of expression of MAGE-Al was determined using cell line LB 11 -
- ID NOS: 3 & 4 had been used as primers. All corresponded to MAGE-Al 0.
- a cDNA library was prepared from a MAGE-A positive sample, following
- samples were homogenized in guanidine thiocyanate to form a lysate
- poly(A)+ RNA was converted to cDNA with an oligo(dT) primer which contained a Notl restriction site.
- the resulting cDNA was ligated to BstXI adaptors, digested with Notl,
- microwell plate 100 ⁇ ls per microwell. Two or three plates were seeded from every
- pooled to obtain 20 different pools from every plate (i.e., 8 pools from lines, and 12 pools
- the PCR assays were carried out on both the living and frozen bacteria, with the
- the number of positive wells in a plate was less than 20%.
- the likelihood of having a single clone in a well should be 90% or greater. Limiting dilution could be carried out to the point where less than 10% of the wells are positive,
- MZ2-MEL43 1/5,000 ( 18) 1/6 200 (16) 1/5,000 (20) 0/100 000 1/500 000 1/5,000 (20) 0/100,000 0/100 000 0/100,000 1/6 600 (15) 0/100 000 0/ 100 000
- TT-THYR 1/21 600 (5) 1/ 12 000 (9) 1/15,400 (7) 1/6 300 (17) 0/108 000 1/18,000 (6) 0/108 000 1/12,000 (9) 0/800 000 0/108,000 0/108,000 1/12,000 (9)
- the first line gives the abundance of cloned MAGE-A cDNAs in the library calculated, according to the Poisson distribution, from 10 the number of microwel Is scored positive by the PCR assay (number in brackets)
- One microwell contained 350 to 860 different clones.
- the second line gives the results of PCR assays performed on uncloned cDNAs
- the level of expression evaluated by the Intensity of the band obtained by separating PCR products in agarose gels is represented +++, +++, ++, + or +/- Absence of product is indicated by -
- the first estimation was obtained with previously described primers (De Plaen et al , 1994)
- a second one presented in brackets for genes MAGE-Al , 9 and 10 was obtained with recently developed pairs of primers
- primers and a level of expression was estimated based upon intensity of banding on an
- the limiting dilution assay revealed a level of expression of MAGE- A 10 which was
- SEQ ID NOS: 7 and 8 are better at determining expression levels.
- MAGE-A 10 showed the highest level of expression
- A1-A7 A9 and A12 were not found at all among 230,000 clones analyzed.
- the method involves preparing cDNA from a sample,
- transformants/transfectants These cells are then divided into a plurality of samples of
- the number of positive samples should be less than or equal to 20% of
- the frequency of each MAGE cDNA is determined.
- the method is carried out by distributing the samples in a predetermined
- cDNA had not been isolated previously, and is a further feature of the invention, i.e., isolated
- nucleic acid molecules such as the one
- nucleic acid molecules i.e., all of the nucleic acid molecules described herein, can be used
- expression vectors which comprise the nucleic acid molecule operably linked to a
- nucleic acid molecules can also be used both diagnostically and therapeutically.
- a sample such as a cell containing sample, a cell lysate, etc.
- oligomer for expression of the nucleic acid molecules described herein, using oligomer
- MAGE nucleic acid molecule of interest For example SEQ ID NO: 9 and or SEQ ID NO:
- SEQ ID NO: 11 and/or 12 can be used to determine
- peptides consisting of from about 8 to about 25 amino acids
- Such peptides are specific binders for MHC molecules, such as
- HLA molecules such as HLA-Al, A2, A3,
- amino acid sequences are set out at SEQ ID NOS:21-24, where SEQ ID NO:21 is that for
- SEQ ID NO:22 is that for MAGE A8
- SEQ ID NO:23 is that for MAGE A9
- SEQ ID NO:24 is that for MAGE Al 1 :
- compositions based upon these molecules are also a part of the invention, such as
- compositions containing a MAGE protein in accordance with the invention and a
- a pharmaceutically acceptable adjuvant such as a cytokine, an interleukin (e.g., IL-2JL-4, IL-
- dendritic cells which may be treated to be rendered non-proliferative, etc.
- peptides or proteins may be used in the form of appropriate compositions, such as in liposome
- compositions based compositions. Also a part of the invention are isolated cytolytic T cell lines which are
- a further aspect of the invention are so-called "mini genes" which carry information
- Mini genes can be designed which encode one or more antigenic peptides, and
- vaccinia or adenoviruses See, e.g., Zajac, et al, Int. J. Cancer 71 : 496 (1997), incorporated
- recombinant vectors such as recombinant vaccinia virus vectors
- fusion proteins can be constructed so as to produce fusion proteins.
- fusion proteins can be constructed where one portion of the fusion protein is the desired tumor rejection antigen precursor, or
- tumor rejection antigen and additional protein or peptide segments can be included.
- reporter proteins or peptides i.e., proteins or peptides
- fluoresence protein Additional reporter proteins include, but are by no means limited to,
- proteins such as ⁇ galactosidase, luciferase, dhfr, and "eGFP", or enhanced green fluorescent
- GFP and eGFP
- the fusion protein can include more than one tumor rejection antigen,
- proteins or peptides which facilitate the delivery of
- peptides are well known to the art, and need not be elaborated herein.
- Such cells may be, e.g., any type of eukaryotic cell, with human cells being especially preferred. Such cells can then be used, e.g., to
- tumor rejection antigen precursors or tumor rejection antigens are produced. They can also be produced tumor rejection antigen precursors or tumor rejection antigens. They can also be produced tumor rejection antigen precursors or tumor rejection antigens. They can also be produced tumor rejection antigen precursors or tumor rejection antigens. They can also be produced tumor rejection antigen precursors or tumor rejection antigens. They can also be produced tumor rejection antigen precursors or tumor rejection antigens. They can also be produced tumor rejection antigen precursors or tumor rejection antigens. They can also be produced tumor rejection antigen precursors or tumor rejection antigens. They can also be produced tumor rejection antigen precursors or tumor rejection antigens. They can also be produced tumor rejection antigens. They can also be produced tumor rejection antigens. They can also be produced tumor rejection antigen precursors or tumor rejection antigens. They can also be produced tumor rejection antigens. They can also be produced tumor rejection antigens. They can also be produced tumor rejection antigens. They can also be produced tumor rejection antigens. They can also be produced tumor rejection antigens.
- MHC molecules and tumor rejection antigens This can be done simply by contacting the
- transfected cells to a source of T cells, such as a blood sample, so as to provoke the
- TRAs i.e., tumor rejection antigens
- Such cells when rendered non-proliferative, can also be used as
- the vectors can be any type of T cell response in vivo, as is shown herein.
- the vectors can be any type of T cell response in vivo, as is shown herein.
- the vectors can be any type of T cell response in vivo, as is shown herein.
- the vectors can be any type of T cell response in vivo, as is shown herein.
- the vectors can be any type of T cell response in vivo, as is shown herein. Similarly, the vectors can be any type of T cell response in vivo, as is shown herein. Similarly, the vectors can be any type of T cell response in vivo, as is shown herein. Similarly, the vectors can be any type of T cell response in vivo, as is shown herein. Similarly, the vectors can be any type of T cell response in vivo, as is shown herein. Similarly, the vectors can be any type of T cell response in vivo, as is shown herein. Similarly, the vectors can be any type of
- T cell used as vaccine materials per se, and can be administered to a patient in need of a T cell
- cells generated ex vivo can also be used to treat patients.
- the peptides may be combined with peptides from other tumor rejection antigens to
- peptides include those listed in U.S. Patent Application Serial
- Polytopes are groups of two or more potentially immunogenic or immune stimulating
- peptides can be joined together directly, or via the use of flanking sequences.
- polytopes can be introduced as polypeptide structures, or via
- nucleic acid delivery systems To elaborate, the art has many different ways available to introduce DNA encoding an individual epitope, or a polytope such as is discussed
- Adenovirus pox-virus, Ty-virus like particles, plasmids, bacteria, etc.
- a feature of the invention is the use of these peptides to determine the presence
- HLA molecules can be "lysed" by adding the peptides of the invention to positive
- TNF production etc. or any other of the methods by which T cell activity is
- TILs lymphocytes
- HLA positive cells to a sample, and determining lysis of the HLA positive cells via, e.g., 51 Cr
- CTL may be detected by ELISPOT analysis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00912112A EP1194542A1 (en) | 1999-03-02 | 2000-03-01 | Cloning of cdna of mage's 5,8,9 and 11 and their uses in diagnosis of cancer |
KR1020017011090A KR20020011967A (en) | 1999-03-02 | 2000-03-01 | Cloning of cDNA of MAGE's 5,8,9 and 11 and their uses in diagnosis of cancer |
AU33895/00A AU3389500A (en) | 1999-03-02 | 2000-03-01 | Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer |
JP2000602775A JP2003512814A (en) | 1999-03-02 | 2000-03-01 | Cloning of cDNAs of MAGEs 5, 8, 9 and 11 and their use in diagnosing cancer |
CA002366059A CA2366059A1 (en) | 1999-03-02 | 2000-03-01 | Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26097899A | 1999-03-02 | 1999-03-02 | |
US09/260,978 | 1999-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000052163A1 true WO2000052163A1 (en) | 2000-09-08 |
Family
ID=22991462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/005346 WO2000052163A1 (en) | 1999-03-02 | 2000-03-01 | Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1194542A1 (en) |
JP (1) | JP2003512814A (en) |
KR (1) | KR20020011967A (en) |
AU (1) | AU3389500A (en) |
CA (1) | CA2366059A1 (en) |
NZ (1) | NZ513739A (en) |
WO (1) | WO2000052163A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007053956A1 (en) | 2005-11-14 | 2007-05-18 | Universite Laval | Cancer antigen mage-a9 and uses thereof |
US10377803B1 (en) | 2017-07-07 | 2019-08-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10472402B2 (en) | 2017-07-07 | 2019-11-12 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
FR3087448A1 (en) | 2018-10-23 | 2020-04-24 | Pdc Line Pharma | MODIFIED PDC LINE TO SECRET A CYTOKINE |
US11433099B2 (en) | 2018-12-18 | 2022-09-06 | Immatics Biotechnologies Gmbh | Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992020356A1 (en) * | 1991-05-23 | 1992-11-26 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
US5612201A (en) * | 1991-05-23 | 1997-03-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
-
2000
- 2000-03-01 EP EP00912112A patent/EP1194542A1/en not_active Withdrawn
- 2000-03-01 NZ NZ513739A patent/NZ513739A/en not_active Application Discontinuation
- 2000-03-01 WO PCT/US2000/005346 patent/WO2000052163A1/en not_active Application Discontinuation
- 2000-03-01 KR KR1020017011090A patent/KR20020011967A/en not_active Application Discontinuation
- 2000-03-01 JP JP2000602775A patent/JP2003512814A/en active Pending
- 2000-03-01 CA CA002366059A patent/CA2366059A1/en not_active Abandoned
- 2000-03-01 AU AU33895/00A patent/AU3389500A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992020356A1 (en) * | 1991-05-23 | 1992-11-26 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
US5612201A (en) * | 1991-05-23 | 1997-03-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
Non-Patent Citations (3)
Title |
---|
JURK, M. ET AL.: "MAGE-11 protein is highly conserved in higher organisms and located predominantly in the nucleus.", INTERNATIONAL JOURNAL OF CANCER, vol. 75, no. 5, 2 March 1998 (1998-03-02), pages 762 - 6, XP000915075 * |
PLAEN DE E ET AL: "STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION OF 12 GENES OF THE MAGE FAMILY", IMMUNOGENETICS,DE,SPRINGER VERLAG, BERLIN, vol. 40, no. 5, 1 January 1994 (1994-01-01), pages 360 - 369, XP000614537, ISSN: 0093-7711 * |
SERRANO, A. ET AL.: "Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries.", INTERNATIONAL JOURNAL OF CANCER, vol. 83, no. 5, 26 November 1999 (1999-11-26), pages 664 - 9, XP000915131 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007053956A1 (en) | 2005-11-14 | 2007-05-18 | Universite Laval | Cancer antigen mage-a9 and uses thereof |
EP1951891A1 (en) * | 2005-11-14 | 2008-08-06 | Universite Laval | Cancer antigen mage-a9 and uses thereof |
EP1951891A4 (en) * | 2005-11-14 | 2009-02-25 | Univ Laval | Cancer antigen mage-a9 and uses thereof |
EP2305827A1 (en) * | 2005-11-14 | 2011-04-06 | Université Laval | Cancer antigen MAGE-A9 and uses thereof |
US11001616B2 (en) | 2017-07-07 | 2021-05-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10435449B2 (en) | 2017-07-07 | 2019-10-08 | Inmatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10377803B1 (en) | 2017-07-07 | 2019-08-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11168122B2 (en) | 2017-07-07 | 2021-11-09 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10450357B2 (en) | 2017-07-07 | 2019-10-22 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10472402B2 (en) | 2017-07-07 | 2019-11-12 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10597434B2 (en) | 2017-07-07 | 2020-03-24 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11866473B2 (en) | 2017-07-07 | 2024-01-09 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11618774B2 (en) | 2017-07-07 | 2023-04-04 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10711048B2 (en) | 2017-07-07 | 2020-07-14 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10800823B2 (en) | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10836806B2 (en) | 2017-07-07 | 2020-11-17 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10899807B2 (en) | 2017-07-07 | 2021-01-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10899808B2 (en) | 2017-07-07 | 2021-01-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10899809B2 (en) | 2017-07-07 | 2021-01-26 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10947286B2 (en) | 2017-07-07 | 2021-03-16 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10392427B1 (en) | 2017-07-07 | 2019-08-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11261224B2 (en) | 2017-07-07 | 2022-03-01 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US10385105B1 (en) | 2017-07-07 | 2019-08-20 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11292821B2 (en) | 2017-07-07 | 2022-04-05 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11352401B1 (en) | 2017-07-07 | 2022-06-07 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11370817B2 (en) | 2017-07-07 | 2022-06-28 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11407798B2 (en) | 2017-07-07 | 2022-08-09 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11414471B2 (en) | 2017-07-07 | 2022-08-16 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11414470B2 (en) | 2017-07-07 | 2022-08-16 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11414472B2 (en) | 2017-07-07 | 2022-08-16 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11414473B2 (en) | 2017-07-07 | 2022-08-16 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11427622B2 (en) | 2017-07-07 | 2022-08-30 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11498948B2 (en) | 2017-07-07 | 2022-11-15 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11459366B2 (en) | 2017-07-07 | 2022-10-04 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11459365B2 (en) | 2017-07-07 | 2022-10-04 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
US11479589B2 (en) | 2017-07-07 | 2022-10-25 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
WO2020083974A1 (en) | 2018-10-23 | 2020-04-30 | Pdc Line Pharma | Modified pdc line for secreting a cytokine |
FR3087448A1 (en) | 2018-10-23 | 2020-04-24 | Pdc Line Pharma | MODIFIED PDC LINE TO SECRET A CYTOKINE |
US11433099B2 (en) | 2018-12-18 | 2022-09-06 | Immatics Biotechnologies Gmbh | Immunotherapy with B*08 restricted peptides and combination of peptides against cancers and related methods |
US11779605B2 (en) | 2018-12-18 | 2023-10-10 | Immatics Biotechnologies Gmbh | Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods |
Also Published As
Publication number | Publication date |
---|---|
KR20020011967A (en) | 2002-02-09 |
AU3389500A (en) | 2000-09-21 |
CA2366059A1 (en) | 2000-09-08 |
EP1194542A1 (en) | 2002-04-10 |
JP2003512814A (en) | 2003-04-08 |
NZ513739A (en) | 2001-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0711173B1 (en) | Isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof | |
JP3433322B2 (en) | Nucleic acid molecules encoding tumor rejection antigen precursors | |
US5830753A (en) | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. | |
JP5627180B2 (en) | Tumor-associated peptide that binds to human leukocyte antibody (HLA) class II molecules indiscriminately | |
WO1996010577A9 (en) | Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof | |
CN103394079A (en) | Cancer vaccine composition | |
US20190060433A1 (en) | Kif20a epitope peptides for th1 cells and vaccines containing the same | |
EP1230261B1 (en) | Ny-eso-1 nonapeptide derivatives, and uses thereof | |
WO2000052163A1 (en) | Cloning of cdna of mage's 5, 8, 9 and 11 and their uses in diagnosis of cancer | |
JP4365405B2 (en) | Tumor associated peptides that bind to MHC molecules | |
JP4190291B2 (en) | Polynucleotides useful for regulating cancer cell growth | |
JP4174570B2 (en) | Isolated peptides that bind to HLA-C molecules and uses thereof | |
WO2010113495A1 (en) | C6orf167 peptides and vaccines containing the same | |
AU2001293051A1 (en) | Isolated peptides which bind to HLA-C molecules and uses thereof | |
EP1403283A1 (en) | Tumor antigen | |
JP3355360B2 (en) | Isolated peptide | |
JP5736334B2 (en) | Tumor-associated peptide that binds to human leukocyte antibody (HLA) class II molecules indiscriminately | |
JP5736333B2 (en) | Tumor-associated peptide that binds to human leukocyte antibody (HLA) class II molecules indiscriminately | |
KR20130033367A (en) | Ect2 peptides and vaccines including the same | |
EP1301624A2 (en) | Preprocalcitonin as tumor rejection antigen precursor and uses thereof | |
CA2165435C (en) | Isolated peptides which form complexes with mhc molecule hla-c-clone 10 and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR NZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 33895/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2366059 Country of ref document: CA Ref country code: CA Ref document number: 2366059 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 513739 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 602775 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017011090 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000912112 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 1020017011090 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000912112 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000912112 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020017011090 Country of ref document: KR |